ERBB2 and breast cancer: Newly approved drugs targeting the AKT/mTOR pathway in ER+, HR+, and HER2- breast cancers include Gedatolisib, MK-2206, Capivasertib, Sirolimus, Temsirolimus, Sapanisertib, and Vistusertib.